Scynexis Inc (SCYX) - Net Assets
Based on the latest financial reports, Scynexis Inc (SCYX) has net assets worth $49.38 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($59.03 Million) and total liabilities ($9.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Scynexis Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $49.38 Million |
| % of Total Assets | 83.65% |
| Annual Growth Rate | N/A |
| 5-Year Change | 19.68% |
| 10-Year Change | 41.81% |
| Growth Volatility | 622.55 |
Scynexis Inc - Net Assets Trend (2012–2025)
This chart illustrates how Scynexis Inc's net assets have evolved over time, based on quarterly financial data. Also explore Scynexis Inc assets under control for the complete picture of this company's asset base.
Annual Net Assets for Scynexis Inc (2012–2025)
The table below shows the annual net assets of Scynexis Inc from 2012 to 2025. For live valuation and market cap data, see market value of Scynexis Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $49.38 Million | -10.35% |
| 2024-12-31 | $55.08 Million | -24.51% |
| 2023-12-31 | $72.96 Million | +2156.79% |
| 2022-12-31 | $3.23 Million | -92.16% |
| 2021-12-31 | $41.26 Million | +81.29% |
| 2020-12-31 | $22.76 Million | +76.49% |
| 2019-12-31 | $12.89 Million | -58.70% |
| 2018-12-31 | $31.23 Million | +45.84% |
| 2017-12-31 | $21.41 Million | -38.51% |
| 2016-12-31 | $34.82 Million | -17.00% |
| 2015-12-31 | $41.95 Million | +25.48% |
| 2014-12-31 | $33.43 Million | +484.26% |
| 2013-12-31 | $-8.70 Million | +54.99% |
| 2012-12-31 | $-19.33 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Scynexis Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 30232800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $46.00K | 0.09% |
| Other Components | $434.47 Million | 879.93% |
| Total Equity | $49.38 Million | 100.00% |
Scynexis Inc Competitors by Market Cap
The table below lists competitors of Scynexis Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Star Equity Holdings Inc
NASDAQ:STRR
|
$36.10 Million |
|
Swiss Properties Invest A/S
CO:SWISS
|
$36.11 Million |
|
Dividend Select 15 Corp
TO:DS
|
$36.14 Million |
|
Heimstaden AB Pfd.
ST:HEIM-PREF
|
$36.14 Million |
|
Citigold Corporation Ltd
AU:CTO
|
$36.09 Million |
|
AKKO Invest Nyrt
BUD:AKKO
|
$36.08 Million |
|
FERRO-ALLOY RES.
F:5PE
|
$36.08 Million |
|
Mas Murni Indonesia Tbk
JK:MAMI
|
$36.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scynexis Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 55,077,000 to 49,376,000, a change of -5,701,000 (-10.4%).
- Net loss of 8,609,000 reduced equity.
- Other factors increased equity by 2,908,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.61 Million | -17.44% |
| Other Changes | $2.91 Million | +5.89% |
| Total Change | $- | -10.35% |
Book Value vs Market Value Analysis
This analysis compares Scynexis Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.00x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-122.24 | $0.99 | x |
| 2013-12-31 | $-55.02 | $0.99 | x |
| 2014-12-31 | $56.31 | $0.99 | x |
| 2015-12-31 | $34.49 | $0.99 | x |
| 2016-12-31 | $18.29 | $0.99 | x |
| 2017-12-31 | $8.00 | $0.99 | x |
| 2018-12-31 | $7.12 | $0.99 | x |
| 2019-12-31 | $2.30 | $0.99 | x |
| 2020-12-31 | $2.12 | $0.99 | x |
| 2021-12-31 | $1.56 | $0.99 | x |
| 2022-12-31 | $0.08 | $0.99 | x |
| 2023-12-31 | $1.51 | $0.99 | x |
| 2024-12-31 | $1.14 | $0.99 | x |
| 2025-12-31 | $0.99 | $0.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scynexis Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -41.79%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.20x
- Recent ROE (-17.44%) is above the historical average (-212.80%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -68.17% | 1.39x | 0.00x | $-9.54 Million |
| 2013 | 0.00% | -180.70% | 1.36x | 0.00x | $-29.59 Million |
| 2014 | -12.66% | -337.10% | 0.03x | 1.19x | $-7.58 Million |
| 2015 | -77.77% | -12693.77% | 0.01x | 1.17x | $-36.82 Million |
| 2016 | -86.13% | -11668.87% | 0.00x | 1.72x | $-33.47 Million |
| 2017 | -117.05% | -9750.97% | 0.01x | 2.14x | $-27.20 Million |
| 2018 | -39.93% | -4851.36% | 0.00x | 1.70x | $-15.59 Million |
| 2019 | -416.52% | -44388.43% | 0.00x | 4.43x | $-55.00 Million |
| 2020 | -242.49% | -457.97% | 0.12x | 4.51x | $-57.46 Million |
| 2021 | -79.66% | -249.68% | 0.11x | 2.90x | $-36.99 Million |
| 2022 | -1942.75% | -1233.73% | 0.06x | 27.16x | $-63.13 Million |
| 2023 | 91.88% | 47.84% | 1.09x | 1.76x | $59.74 Million |
| 2024 | -38.65% | -568.29% | 0.04x | 1.65x | $-26.80 Million |
| 2025 | -17.44% | -41.79% | 0.35x | 1.20x | $-13.55 Million |
Industry Comparison
This section compares Scynexis Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $236,113,024
- Average return on equity (ROE) among peers: -47.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scynexis Inc (SCYX) | $49.38 Million | 0.00% | 0.20x | $36.09 Million |
| Aurora Cannabis Inc (ACB) | $602.92 Million | -11.50% | 0.39x | $197.35 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $54.20 Million | -73.99% | 0.03x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $1.77 Billion |
| Amphastar P (AMPH) | $639.42 Million | 21.51% | 1.37x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $40.96 Million | 0.73% | 0.09x | $1.80 Billion |
About Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory inva… Read more